menu
    • menu

    Company profile for Orion Corporation

    NEW Drugs in Dev: 33
    Fermion-PSE
    News
    Orion Corporation Reports BlackRock Shareholding Disclosure

    05 Jun 2026

    // GLOBENEWSWIRE

    Orion Corp. Reveals Blackrock, Inc. Stake Per Securities Market

    01 Jun 2026

    // GLOBENEWSWIRE

    Orion Reports First Phase 1/2 Data for ODM-212 in Solid Tumours

    30 May 2026

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Fermion

    Contact Supplier

    Website

    PEGS Boston Summit

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/prostaglandin-market-to-cross-us-1-27-bn-by-2035-liquidia-s-yutrepia-okayed-for-pulmonary-hypertension

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics, etc.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Orion CorporationFinland Flag
    Country
    Country
    Finland
    Address
    Address
    Head officeOrion CorporationOrionintie 1A, FI-02200 Espoo, FinlandP.O.Box 65, ...
    Telephone
    Telephone
    +358 10 4261
    Client Email
    Email
    fermionSales@fermion.fi
    Client Website
    Website
    https://www.orion.fi/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orion-corporation/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 9981

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share
    US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

    US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

    The pharmaceutical industry in the United States continued to grapple with drug shortages during the first quarter (Q1) of 2025. According to the American Society of Health‑System Pharmacists (ASHP), the total number of active shortages stood at 270 as of March 31, 2025 — only slightly below the 277 reported in September 2024, but down 16.4 percent from an all‑time high of 323 reported in Q1 2024.These numbers imply that while dramatic surges in drug shortages may have subsided, underlying vulnerabilities in manufacturing, supply chains, and raw‑material sourcing continue to frustrate efforts towards a durable resolution.A deeper analysis of these drug scarcities reveals that 41 percent of the 270 active shortages first emerged in 2022 or earlier. This implies that many of the current disruptions have become chronic in nature and are exerting pressure on pharmacy operations. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available)CNS drugs dominate with 49 meds in short supply; antimicrobials face shortage of 39 drugsClass‑specific analysis reveals that central nervous system (CNS) agents remained the most disrupted category, with 49 distinct CNS drugs having faced scarcities during Q1. This group spans anxiolytics (anti-anxiety drugs) such as clonazepam and flurazepam, sedatives like lorazepam and midazolam, and stimulants such as methylphenidate and lisdexamfetamine. These shortages pose two challenges — controlling seizures and managing sedation in acute care settings. After CNS agents, antimicrobials was the second‑largest category, with shortages affecting 39 drugs. Key antibacterial and anti-fungal agents such as cefotaxime sodium powder for injection, clindamycin phosphate, rifampin, and metronidazole find themselves on ASHP’s active‑shortage roster, threatening both routine hospital protocols and emergency sepsis management.Fluids and electrolytes occupied the third spot, with 29 items facing shortage in Q1 2025. Hormone agents, including insulin analogs, ranked fourth with 24 drugs in short supply.Chemotherapy medications rounded out the top five categories, with 23 antineoplastic agents (a broad class of medications used to treat cancer) flagged as actively constrained in Q1 2025. Notable shortages included azacitidine, carboplatin, methotrexate, and streptozocin. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) US faces 26 new shortages; Pharmacopeia list warns of 100 vulnerable medicationsThe first quarter saw the emergence of 26 new shortage declarations, emphasizing that even drugs previously deemed reliably sourced can fall into scarcity. The US has been facing a shortage of attention deficit hyperactivity disorder (ADHD) drugs since 2022. The new shortages included ADHD transdermal patch methylphenidate, peginterferon alfa‑2a (Pegasys) used in chronic hepatitis B and C, and bacitracin ophthalmic ointment.The fragility of the pharmaceutical supply chains has been particularly evident in the aftermath of natural disasters. Hurricane Helene’s flooding at Baxter’s Marion, North Carolina, facility deeply affected IV‑solution supply lines. Baxter supplies roughly 60 percent of the US’ IV fluids and the ASHP report listed “hurricane” as the reason behind nine percent of drug shortages, as of January 2025.Regulatory and policy interventions continue to evolve. The US Pharmacopeia’s inaugural Vulnerable Medicines List, launched in 2025, identifies 100 drugs at the highest risk of future shortages, with a particular focus on injectables (comprising 71 percent of the list) and essential hospital care.Antibiotics, medications for pain management and oncology are the other drugs on the list. Although 61 percent of these vulnerable medicines were not in active shortage at the time of listing, their inclusion is intended to galvanize manufacturers and purchasing organizations to bolster inventories.Meanwhile, the Government Accountability Office in the US has called on the Department of Health and Human Services (HHS) to establish a formal coordination mechanism, warning that elimination of the HHS supply‑chain coordinator role in May 2025 risks fragmenting federal response efforts. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Global shortages mirror US patterns; Europe launches monitoring platform Globally, we notice comparable trends. For instance, Europe has rolled out the European Shortages Monitoring Platform (ESMP) this year in order to centralize shortage reporting across member states. Critical‑medicine shortages in the EU — in areas such as oncology, ADHD, and critical care analgesics — mirror US patterns. The European Medicines Agency’s shortage list currently holds 37 human drugs.According to Health Canada’s May 12, 2025 update, its Tier 3 list had 18 drug shortages that are considered to have the greatest impact on Canada’s drug supply and health‑care system. Tier 3 designation is based on medical necessity and minimal availability of alternatives.In hematology and oncology, scarcity of essential drugs like Oncaspar for acute lymphoblastic leukemia, idarubicin and lomustine for leukemias and brain tumors, anagrelide for thrombocythemia, and preservative‑free methotrexate for various malignancies underscore the impact these drug shortages can have on treatment. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Our viewThe global pharma supply chain is dealing with a fresh wave of uncertainties, especially with the likelihood of tariffs on drugs imported into the US. Analysts warn that the proposed pharmaceutical tariffs could exacerbate supply issues.Over 50 percent of drugs used in the US are manufactured abroad. Generic sterile injectable drugs — like chemotherapy medications and IV saline — are particularly vulnerable due to their complex manufacturing processes and low profit margins. Generic drugs (which account for 90 percent of prescriptions filled in the US) could face increased pressure, as many rely on raw materials from China and India. This could result in more severe drug shortages in the future. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 5325

    https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities

    #PharmaFlow by PHARMACOMPASS
    22 May 2025
    Share Share
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 16396

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Orion Corporation Reports BlackRock Shareholding Disclosure
    Orion Corporation Reports BlackRock Shareholding Disclosure

    05 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/05/3307456/0/en/orion-corporation-disclosure-under-chapter-9-section-10-of-the-securities-market-act-blackrock-inc.html

    GLOBENEWSWIRE
    05 Jun 2026
    Share Share
    Orion Corp. Reveals Blackrock, Inc. Stake Per Securities Market
    Orion Corp. Reveals Blackrock, Inc. Stake Per Securities Market

    01 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/01/3304207/0/en/orion-corporation-disclosure-under-chapter-9-section-10-of-the-securities-market-act-blackrock-inc.html

    GLOBENEWSWIRE
    01 Jun 2026
    Share Share
    Orion Reports First Phase 1/2 Data for ODM-212 in Solid Tumours
    Orion Reports First Phase 1/2 Data for ODM-212 in Solid Tumours

    30 May 2026

    // PRESS RELEASE

    https://www.orionpharma.com/newsroom/all-news/releases/press-releases/2026/orion-pharma-announces-first-results-from-phase-12-teades-trial-with-tead-inhibitor-odm-212-in-patients-with-advanced-solid-tumours/

    PRESS RELEASE
    30 May 2026
    Share Share
    Orion Pharma To Unveil TEAD Inhibitor ODM-212 Data At 2026 ASCO
    Orion Pharma To Unveil TEAD Inhibitor ODM-212 Data At 2026 ASCO

    21 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/21/3299033/0/en/orion-pharma-to-present-its-first-clinical-data-from-phase-1-2-teades-trial-of-tead-inhibitor-odm-212-at-the-2026-asco-annual-meeting.html

    GLOBENEWSWIRE
    21 May 2026
    Share Share
    Orion Corp: Karen Lykke Sørensen's Transactions
    Orion Corp: Karen Lykke Sørensen's Transactions

    04 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/04/3286756/0/en/orion-corporation-managers-transactions-karen-lykke-s%c3%b8rensen.html

    GLOBENEWSWIRE
    04 May 2026
    Share Share
    Orion Corp: Sophie Papa's Managers' Transactions
    Orion Corp: Sophie Papa's Managers' Transactions

    04 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/04/3286758/0/en/orion-corporation-managers-transactions-sophie-papa.html

    GLOBENEWSWIRE
    04 May 2026
    Share Share

    FDA Orange Book

    read-more
    read-more

    01

    Brand Name : STALEVO 50

    Finland
    PEGS Boston Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code : AB

    CARBIDOPA; ENTACAPONE; LEVODOPA

    Orion Corporation

    Dosage Form : TABLET; ORAL

    Proprietary Name : STALEVO 50

    Dosage Strength : 12.5MG;200MG;50MG

    Approval Date : 2003-06-11

    Application Number : 21485

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code : AB

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : STALEVO 100

    Finland
    PEGS Boston Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code : AB

    CARBIDOPA; ENTACAPONE; LEVODOPA

    Orion Corporation

    Dosage Form : TABLET; ORAL

    Proprietary Name : STALEVO 100

    Dosage Strength : 25MG;200MG;100MG

    Approval Date : 2003-06-11

    Application Number : 21485

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code : AB

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : STALEVO 150

    Finland
    PEGS Boston Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code : AB

    CARBIDOPA; ENTACAPONE; LEVODOPA

    Orion Corporation

    Dosage Form : TABLET; ORAL

    Proprietary Name : STALEVO 150

    Dosage Strength : 37.5MG;200MG;150MG

    Approval Date : 2003-06-11

    Application Number : 21485

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code : AB

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : STALEVO 200

    Finland
    PEGS Boston Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code : AB

    CARBIDOPA; ENTACAPONE; LEVODOPA

    Orion Corporation

    Dosage Form : TABLET; ORAL

    Proprietary Name : STALEVO 200

    Dosage Strength : 50MG;200MG;200MG

    Approval Date : 2007-08-02

    Application Number : 21485

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code : AB

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : STALEVO 75

    Finland
    PEGS Boston Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code : AB

    CARBIDOPA; ENTACAPONE; LEVODOPA

    Orion Corporation

    Dosage Form : TABLET; ORAL

    Proprietary Name : STALEVO 75

    Dosage Strength : 18.75MG;200MG;75MG

    Approval Date : 2008-08-29

    Application Number : 21485

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code : AB

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : STALEVO 125

    Finland
    PEGS Boston Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code : AB

    CARBIDOPA; ENTACAPONE; LEVODOPA

    Orion Corporation

    Dosage Form : TABLET; ORAL

    Proprietary Name : STALEVO 125

    Dosage Strength : 31.25MG;200MG;125MG

    Approval Date : 2008-08-29

    Application Number : 21485

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code : AB

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : COMTAN

    Finland
    PEGS Boston Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RLD : Yes

    TE Code : AB

    ENTACAPONE

    Orion Corporation

    Dosage Form : TABLET; ORAL

    Proprietary Name : COMTAN

    Dosage Strength : 200MG

    Approval Date : 1999-10-19

    Application Number : 20796

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code : AB

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Europe

    read-more
    read-more

    01

    Brand Name : Sertraline Orion

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Orion Corporation

    Dosage Form : Film Coated Tablet

    Dosage Strength : 50mg

    Packaging :

    Brand Name : Sertraline Orion

    Approval Date : 16-04-2004

    Application Number : 2.00E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Sertraline Orion

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Orion Corporation

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100mg

    Packaging :

    Brand Name : Sertraline Orion

    Approval Date : 16-04-2004

    Application Number : 2.00E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Oralin

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Sertraline Hydrochloride

    Orion Corporation

    Dosage Form : Film Coated Tablet

    Dosage Strength : 50mg

    Packaging :

    Brand Name : Oralin

    Approval Date : 07-12-2007

    Application Number : 2.01E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Oralin

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Sertraline Hydrochloride

    Orion Corporation

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100mg

    Packaging :

    Brand Name : Oralin

    Approval Date : 07-12-2007

    Application Number : 2.01E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Vancomycin Orion

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Vancomycin Hydrochloride

    Orion Corporation

    Dosage Form : Powder For Concentrate For Sol...

    Dosage Strength : 500mg

    Packaging :

    Brand Name : Vancomycin Orion

    Approval Date : 10-09-2015

    Application Number : 2.01E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Vancomycin Orion

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Vancomycin Hydrochloride

    Orion Corporation

    Dosage Form : Powder For Concentrate For Sol...

    Dosage Strength : 1000mg

    Packaging :

    Brand Name : Vancomycin Orion

    Approval Date : 10-09-2015

    Application Number : 2.01E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Vancomycin Orion

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Vancomycin Hydrochloride

    Orion Corporation

    Dosage Form : Powder For Concentrate For Sol...

    Dosage Strength : 500mg

    Packaging :

    Brand Name : Vancomycin Orion

    Approval Date : 27-02-2024

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Vancomycin Orion

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Vancomycin Hydrochloride

    Orion Corporation

    Dosage Form : Powder For Concentrate For Sol...

    Dosage Strength : 1000mg

    Packaging :

    Brand Name : Vancomycin Orion

    Approval Date : 27-02-2024

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Abiraterone Orion

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Abiraterone Acetate

    Orion Corporation

    Dosage Form : Film Coated Tablet

    Dosage Strength : 500mg

    Packaging :

    Brand Name : Abiraterone Orion

    Approval Date : 24-05-2021

    Application Number : 2.02E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Prose

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Acetylsalicylic Acid

    Orion Corporation

    Dosage Form : Tablet

    Dosage Strength : 75mg

    Packaging :

    Brand Name : Prose

    Approval Date : 10-05-2019

    Application Number : 2.02E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Canada

    read-more
    read-more

    01

    Brand Name : N/A

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Generic

    Registration Country : Canada

    Alprazolam

    Orion Corporation

    Dosage Form : TABLET

    Dosage Strength : 0.25MG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number : 74085

    Regulatory Info : Generic

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : N/A

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Generic

    Registration Country : Canada

    Alprazolam

    Orion Corporation

    Dosage Form : TABLET

    Dosage Strength : 0.5MG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number : 78056

    Regulatory Info : Generic

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : N/A

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Generic

    Registration Country : Canada

    Alprazolam

    Orion Corporation

    Dosage Form : TABLET

    Dosage Strength : 1MG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number : 74294

    Regulatory Info : Generic

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : N/A

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Generic

    Registration Country : Canada

    Alprazolam

    Orion Corporation

    Dosage Form : TABLET

    Dosage Strength : 2MG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number : 74085

    Regulatory Info : Generic

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : ANTISEDAN

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : PRESCRIPTION

    Registration Country : Canada

    ATIPAMEZOLE HYDROCHLORIDE

    Orion Corporation

    Dosage Form : SOLUTION

    Dosage Strength : 5MG/ML

    Packaging : 10ML

    Brand Name : ANTISEDAN

    Approval Date :

    Application Number : 2237744

    Regulatory Info : PRESCRIPTION

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : N/A

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Generic

    Registration Country : Canada

    Beclomethasone Dipropionate

    Orion Corporation

    Dosage Form : NASAL SPRAY

    Dosage Strength : 50MCG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number :

    Regulatory Info : Generic

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : N/A

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Generic

    Registration Country : Canada

    Beclomethasone Dipropionate

    Orion Corporation

    Dosage Form : NASAL SPRAY

    Dosage Strength : 100MCG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number :

    Regulatory Info : Generic

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : N/A

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Generic

    Registration Country : Canada

    Buspirone

    Orion Corporation

    Dosage Form : TABLET

    Dosage Strength : 5MG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number : 202557

    Regulatory Info : Generic

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : N/A

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Generic

    Registration Country : Canada

    Buspirone

    Orion Corporation

    Dosage Form : TABLET

    Dosage Strength : 10MG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number : 75272

    Regulatory Info : Generic

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : N/A

    Finland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Generic

    Registration Country : Canada

    Buspirone

    Orion Corporation

    Dosage Form : TABLET

    Dosage Strength : 15MG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number : 78888

    Regulatory Info : Generic

    Registration Country : Canada

    Fermion Orion Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Check the inspections & registration from this company
    Fermion Orion VB popup

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search